Loading the company…
Loading the company…
Families: Dialysis access, Breast biopsy & localization, Peripheral arterial intervention, Skin substitutes & wound grafts, Radiofrequency ablation (facet, genicular, basivertebral), Tumor & fibroid embolization.
All companies · Product and company coverage
In the last ten years FDA made 11 decisions for Merit Medical Systems (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 6 procedure families, the most in 2026 (2). The latest was on 2026-05-13.
In 2025, Merit Medical Systems reported engagement with 979 surgeons and other clinicians in the states MedaRep covers, worth $737K in consulting, speaking, meals and travel for its device products, the most in California ($191K to 132). Royalties are left out.
| HeRO Graft |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Merit Medical Systems.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: California ($191K, 132 engaged), Utah ($117K, 15 engaged), Texas ($72K, 82 engaged), Florida ($42K, 89 engaged), Illinois ($38K, 23 engaged).